Stop Antibiotics on Procalcitonin guidance Study

Completed

Conditions: infection
Sepsis
10004018

Registration Number: NL-OMON38095

Lead Sponsor: Vrije Universiteit Medisch Centrum

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 1816

Inclusion Criteria

A patient over the age of 18, admitted to the ICU and receiving antibiotics for less than 24 hours for (suspected) bacterial infections

Exclusion Criteria

Failure to obtain written consent to participate
Patients receiving prolonged antibiotic therapies (> 3 weeks, e.g. endocarditis, cerebral/hepatic abscess)
Patients with severe infections due to viruses or parasites (e.g. Denguevirus, Toxoplasma gondii, Plasmodium spp.)
Patients infected with Mycobacterium tuberculosis
Patients entering the ICU for post-operative observation and/or on antibiotic prophylaxis with an estimated length of stay less then 24 hrs.
Patients suffering from cystic fibrosis
Severely immunocompromised patients such as patients with HIV and with a CD4 count of less than 200 cells/mm, neutropenic patients (<500 neutrophils per mL) or patients with solid organ transplantation
Moribund patients

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Consumption of antibiotics expressed as the Daily Defined Dosage and duration<br /><br>of antibiotic therapy expressed in days of therapy. In case of multiple<br /><br>antibiotic therapies the therapy that will be used the longest will be scored<br /><br>in duration of therapy.<br /><br><br /><br>28-day and 60-day mortality </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Percentage of new episodes of bacterial infections per 1,000 ICU days<br /><br>Length of ICU stay, measured after discharge from the ICU in days<br /><br>Acquisition costs of antibiotics (in Euro's)<br /><br>Costs of procalcitonin (in Euro's)</p><br>